Title of article
Acute interstitial nephritis with immunotherapy; a growing entity?
Author/Authors
Chetwood, John David Department of General Medicine - Tamworth Hospital, Dean St, Tamworth, NSW, Australia , MyatID, Lin Lin Department of General Medicine - Tamworth Hospital, Dean St, Tamworth, NSW, Australia , Lammi, Helen Department of General Medicine - Tamworth Hospital, Dean St, Tamworth, NSW, Australia , Panat, Mani Department of General Medicine - Tamworth Hospital, Dean St, Tamworth, NSW, Australia , HughesID, James Department of General Medicine - Tamworth Hospital, Dean St, Tamworth, NSW, Australia , Hughes, ames Department of General Medicine - Tamworth Hospital, Dean St, Tamworth, NSW, Australia
Pages
3
From page
1
To page
3
Abstract
We report a case of acute kidney injury (AKI) secondary to immune-mediated acute interstitial nephritis (AIN), with supporting diagnostic results and a successful response to treatment. This entity is gaining increasing recognition with the burgeoning use of immunotherapy agents in oncology. The timeline for the development of AIN from the initiation of immunotherapy varies, and may range in severity from asymptomatic to severe, organ-threatening and with life threatening consequences. Renal biopsy should be performed to confirm the diagnosis due to the potential impact of discontinuation of immunotherapy on cancer survival. Re-challenge with immunotherapy is reasonable once renal function recovers.
Keywords
Acute Interstitial Nephritis , Checkpoint Inhibitor , immunotherapy , Nivolumab
Journal title
Journal of Renal Injury Prevention
Serial Year
2020
Record number
2523427
Link To Document